Malignant pancreatic neoplasm

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

Researchers are testing a chemotherapy combination built around albumin-bound paclitaxel (II) for people with pancreatic cancer. The study has three groups: one for advanced cancer that cannot be removed by surgery, one for cancer that may be removable and receives treatment befo…

Researchers are testing a new immunotherapy called Lm-LLO-TT in adults with advanced pancreatic ductal adenocarcinoma that has already been treated with chemotherapy. Lm-LLO-TT uses a weakened form of Listeria bacteria engineered to carry a tetanus toxoid antigen, aiming to spark…

Researchers are testing whether adding two oral drugs, avutometinib and defactinib, to standard chemotherapy (mFOLFIRINOX) is safe and can slow or shrink pancreatic ductal adenocarcinoma. The trial has two parts: one for people whose cancer has spread, and one for people whose ca…

Researchers are running a first-in-human study of MGC030, an antibody-drug conjugate, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The trial includes participants with urothelial, colorectal, gastric, gastroesophageal, esop…

Pancreatic and other biliopancreatic cancers often block the bile duct, causing jaundice and serious infections. Doctors use endoscopic procedures to place stents that restore bile flow, but several techniques exist and it is unclear which works best. This study follows 300 patie…

Researchers are testing whether combining retlirafusp alfa, famitinib, and AG chemotherapy (nab-paclitaxel plus gemcitabine) can slow cancer growth in people with unresectable pancreatic cancer. The trial enrolls about 88 adults with locally advanced or metastatic pancreatic duct…

Researchers are testing a wafer called EF-009 that surgeons place directly onto pancreatic tumors during a minimally invasive operation. The trial enrolls adults with borderline resectable or unresectable pancreatic cancer, meaning tumors that surgery may or may not be able to re…

Researchers are testing an investigational drug called SKB571 in adults with advanced or metastatic pancreatic cancer. The trial aims to see how well the drug shrinks tumors and how safe it is. Participants receive SKB571 every three weeks, and doctors track their response using …

This trial tests whether an experimental drug called HRS-7172, when combined with other antitumor therapies, can safely shrink or control advanced pancreatic cancer that has RAS mutations or amplifications. The study includes adults aged 18 to 70 with locally advanced or metastat…

This phase III trial tests an experimental drug called YL201 against standard chemotherapy in people with metastatic pancreatic cancer that has progressed after gemcitabine-based treatment. YL201 is designed to deliver a toxin directly to cancer cells that carry a specific marker…

This trial tests whether adding an experimental immunotherapy (SHR-1701) and a targeted drug (apatinib) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with advanced pancreatic cancer. The study enrolls adults aged 18 to 75 who have not yet received trea…

This phase 2 trial tests whether choosing treatment based on the genetic changes in a person's pancreatic cancer works better than standard chemotherapy. Adults with advanced pancreatic cancer that has progressed after first-line treatment may join if their tumor has a genetic ch…

This trial compares two surgical approaches for people with pancreatic cancer in the left side of the pancreas. One method removes the spleen along with the tumor, which is standard practice. The other preserves the spleen, potentially reducing complications and avoiding lifelong…

This trial tests whether giving hydrocortisone during and right after pancreatic surgery can lower the risk of a postoperative pancreatic fistula, a serious leak of digestive fluids. About 20 adults with pancreatic, duodenal, or bile duct cancer will be randomly assigned to recei…

This trial is testing whether a new oral drug called HRS-2329, which blocks multiple RAS proteins, can shrink tumors or slow disease when combined with other anti-cancer therapies. It is enrolling adults with advanced pancreatic cancer that has RAS mutations or amplifications and…

This phase 2 trial is testing whether adding another experimental drug (GFS202A or GFH276) to a targeted therapy (GFH375) works better than GFH375 alone in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already had at…

This trial tests whether a wearable device and a personalized prehabilitation program can help adults recover better after surgery for pancreatic cancer or related conditions. Participants will wear a monitor to track vital signs and activity, and follow a program of exercise, nu…

This phase 2 trial is testing whether combining an experimental drug called retlirafusp alfa with apatinib and chemotherapy can help people with advanced pancreatic cancer whose disease has worsened after initial treatment. The study will enroll about 37 adults with locally advan…

This early-phase trial will test a combination of two drugs—JDB153 (taken as a pill) and serplulimab (given by IV)—in 10 people with advanced pancreatic cancer that has not responded to standard treatments. The main goals are to check safety and see if the drugs can shrink tumors…

This phase 2 trial is testing whether combining two immunotherapy drugs—vilastobart and retifanlimab—can shrink tumors in people with metastatic pancreatic cancer that has a BRCA1, BRCA2, or PALB2 gene mutation. Participants receive both drugs by IV infusion over several months. …

This early-stage trial tests an experimental oral drug called SNV1521, a PARP inhibitor, combined with the RAS-targeting medicine daraxonrasib in adults with pancreatic cancer that cannot be surgically removed or has spread. The main goals are to find safe and tolerable doses of …

This early-phase trial tests an experimental drug called XNW28012 in people with metastatic pancreatic cancer whose disease has worsened after at least one prior treatment. XNW28012 is an antibody-drug conjugate designed to seek out a protein called tissue factor on cancer cells …

This early-phase trial tests an experimental drug, KGX105, in people with advanced solid tumors that have not responded to standard treatments. KGX105 is designed to activate immune T-cells specifically within the tumor, potentially reducing side effects. The study will assess sa…

This clinical trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy can help people with borderline resectable or locally advanced pancreatic cancer. The study will enroll 136 adults aged 18-85 with confirmed pancreatic ductal adenocarcinoma. Half will ge…

This study tests a new approach called photoimmunotherapy for people with locally advanced or borderline resectable pancreatic cancer. Patients receive an injection of ASP-1929, a drug that attaches to cancer cells and becomes active when exposed to a specific light. During surge…

This phase 2 trial tests whether adding the experimental drug HRS-4642 to standard chemotherapy, with or without the immunotherapy adebrelimab, can shrink pancreatic tumors before surgery. The study enrolls adults aged 18-70 with pancreatic ductal adenocarcinoma who have at least…

This trial tests a new drug called DN022150 in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already received at least one prior treatment. The study compares DN022150 alone against standard chemotherapy options to s…

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…

This phase 2 trial tests a new treatment approach for people with locally advanced pancreatic cancer that cannot be removed by surgery. Participants receive targeted radiation therapy followed by a combination of two immunotherapy drugs (ipilimumab N01 and sintilimab) plus standa…

This study tests a new drug called samuraciclib added to standard chemotherapy for people with a specific type of advanced pancreatic cancer (basal-like). The goal is to find the safest dose and see if the combination helps shrink tumors or slow the cancer. About 67 adults with n…

This study tests a new drug called DN022150 combined with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. About 465 adults aged 18-75 who have not had prior treatment for advanced disease will tak…

This early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…

This study tests whether a newer, shorter metal stent works better than a standard plastic stent for opening blocked bile ducts in people with pancreatic cancer who need surgery. About 116 adults with operable or locally advanced pancreatic cancer and high bilirubin levels will b…

This early-stage study tests a new treatment called DCTY1102 for people with advanced cancers (like pancreatic, colorectal, or lung cancer) that have a specific genetic change (KRAS/NRAS G12D mutation) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own …

This early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…

This study tests a new treatment for people with advanced pancreatic cancer that has not been treated before. It combines a hedgehog inhibitor (NLM-001) with standard chemotherapy and two immunotherapy drugs. The goal is to see if this combination shrinks tumors better than chemo…

This phase 3 trial tests whether the experimental drug MRG004A, combined with best supportive care, helps people with advanced pancreatic cancer live longer compared to a placebo. The study plans to enroll 231 adults whose cancer has not responded to standard treatments. Particip…

This early-stage trial tests a new therapy called MT-601, which uses a patient's own immune T-cells trained to recognize multiple cancer-related targets. It is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study will check safety …

This study looks at whether adding Shouhui Tongbian capsules to standard pancreatic enzyme therapy can help people digest food better after surgery for pancreatic cancer. About 80 adults who had a Whipple procedure and have digestive issues or constipation will take part. The mai…

This early-stage trial tests a new type of cell therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy. The treatment uses a patient's own immune cells, called macrophages, that are engineered in a lab to recognize and attack cancer cells c…

This phase 2 trial tests an experimental oral liquid called BLEX 404 combined with standard chemotherapy (gemcitabine) in 40 people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study first finds a safe dose, then checks if the combo shrinks…

This early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …

This early-phase trial tests whether delivering the chemotherapy drug gemcitabine directly into the artery feeding the tumor can improve surgical outcomes for people with borderline resectable pancreatic cancer. Ten participants will receive standard chemo and radiation, followed…

This phase 2 trial tests whether giving a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and chemotherapy before surgery can help people with high-risk or borderline resectable pancreatic cancer. The study will enroll 30 participants and track ho…

This Phase 2 trial tests a combination of tunlametinib and anti-EGFR antibodies (cetuximab β or nimotuzumab) in 90 adults with advanced colorectal or pancreatic cancers that have RAS mutations and have not responded to standard treatments. The goal is to see if the combo shrinks …

This study tests whether injecting chemotherapy directly into a pancreatic tumor using an endoscope (EUS-guided) plus standard chemo works better than standard chemo alone. About 20 adults with locally advanced pancreatic cancer will take part. The goal is to see if the combinati…

This study tests a new drug called IBI343 combined with chemotherapy for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. The goal is to shrink the tumor enough so it can be surgically removed, then follow up with more chemo. Abo…

This early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers …

This Phase 3 trial tests whether adding the experimental antibody FG-M108 to standard chemotherapy (gemcitabine and nab-paclitaxel) helps people with advanced pancreatic cancer live longer. About 524 participants with Claudin18.2-positive tumors will be randomly assigned to recei…

This study tests a new drug called IBI363 combined with chemotherapy for people with advanced pancreatic cancer that has worsened after first treatment. About 48 patients will receive the combination to see if it is safe and helps control the cancer. The goal is to slow disease p…

This study tests a new first-line treatment for people with pancreatic cancer that has spread to the liver. The treatment combines chemotherapy delivered directly to the liver with two immunotherapy drugs. The goal is to see if this approach can slow or stop cancer growth. The st…

This study tests a combination of four drugs—tunlametinib, two chemotherapies, and a targeted antibody—as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The trial will enroll 28 patients who have not had prior therapy. Researchers …

This study looks at whether actively treating diabetes with drugs like metformin or insulin can help people with metastatic pancreatic cancer live longer when they also receive standard chemotherapy. About 210 adults with both pancreatic cancer and diabetes will be enrolled. The …

This phase 2 trial tests whether adding nimotuzumab, a targeted antibody, to standard chemotherapy can help people with high-risk pancreatic cancer that can still be surgically removed. About 156 participants will receive either the drug combo or a placebo before and after surger…

This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can help shrink pancreatic tumors before surgery. About 30 people with resectable pancreatic cancer will receive the combination, and researchers will measure how many tumors …

This early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goal is to check safety, b…

This phase 2 trial tests whether putting an immunotherapy drug called adebrelimab directly into the chest or belly can help control cancer-related fluid buildup in people with advanced pancreatic cancer. About 20 participants will receive the drug along with standard care. The go…

This study tests whether a specific sequence of two different chemotherapy combinations, each paired with an immunotherapy drug (PD-L1 antibody), can shrink borderline resectable or locally advanced pancreatic cancer enough to allow surgical removal. About 77 adults with this typ…

This phase 2 trial tests whether the drug trilaciclib can protect bone marrow in 96 people with advanced bile duct or pancreatic cancer before they receive chemotherapy. The goal is to reduce serious side effects like low white blood cell counts, which can lead to infections. Par…

This phase 3 trial will test whether giving chemotherapy before surgery helps people with resectable left-sided pancreatic cancer live longer compared to surgery alone. About 381 participants will be randomly assigned to either neoadjuvant chemotherapy (FOLFIRINOX or gemcitabine/…

Researchers are studying whether immune markers in a blood sample taken before pancreatic cancer surgery can predict a serious complication called postoperative pancreatic fistula, where digestive fluids leak from the surgical connection. Adults scheduled for curative-intent panc…

Researchers test a new endoscopic device called the loop brush fine needle aspiration (lbFNA) to sample pancreatic cysts in people scheduled for surgery. The pilot study enrolls 8 adults with cysts that require surgical removal. Doctors use the device to puncture, brush, and aspi…

Pancreatic cancer is hard to catch early, and screening guidelines for high-risk people remain uncertain. Researchers at UNC are testing an electronic decision support tool that guides patients and doctors through a shared conversation about whether to screen. The pilot study enr…

This registry study follows 400 people at increased risk for pancreatic ductal adenocarcinoma who receive PancreaSure, a blood test designed to detect early-stage disease. Researchers track whether the test results lead doctors to change surveillance plans, such as scheduling mor…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This study is testing a new blood test that looks for changes in DNA to help diagnose pancreatic cancer. Researchers will collect blood samples and medical records from 450 people with or at high risk for pancreatic cancer. The goal is to see if this test can find cancer earlier …

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This early-phase study will test two radioactive tracers designed to light up certain solid tumors on scans. Twenty adults with breast, head and neck, pancreatic cancer, or glioma will receive an injection of the tracers and then undergo PET/CT and SPECT/CT imaging. The goal is t…

This early-phase trial tests a new radioactive tracer (64Cu-DOTA-A2DM) for PET scans in people with advanced pancreatic cancer that has spread. The tracer is designed to attach to a protein called PSCA found on some pancreatic cancer cells, making them visible on the scan. The st…

This study tests a new PET imaging tracer, [68Ga]Ga-NODAGA-SNA014, to detect a protein called Claudin18.2 in pancreatic and stomach cancers. The goal is to see if the scan can accurately identify patients whose tumors have this protein, which could help doctors choose the right t…

This study tests a new radioactive imaging agent called 68Ga-NOTA-GPA33 nanobody, which targets a protein (GPA33) found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage colorectal, stomach, and pancreatic cancers in 56 patients…

Researchers are studying whether a procedure called fluoroscopy-guided transdiscal splanchnic nerve neurolysis can safely reduce severe upper abdominal pain in adults with pancreatic, gastric, or hepatobiliary cancer. Participants first receive a diagnostic nerve block with local…

Researchers are testing whether a digital nutrition app called STRONG, paired with remote dietitian counseling, is practical and helpful for adults with pancreatic ductal adenocarcinoma who are starting chemotherapy or radiation. About 80 participants join the study and are assig…

Researchers are testing whether personalised nutritional care from a trained dietitian improves quality of life for people aged 65 and older with pancreatic ductal adenocarcinoma. About 250 participants will be randomly assigned to either six months of individualised nutrition su…

This trial tests whether a traditional Chinese music therapy, called Ziwu Liuzhu Five-Element Music Therapy, can reduce anxiety in people with pancreatic cancer who are undergoing chemotherapy. The study will enroll 320 patients with mild-to-moderate anxiety and randomly assign t…

This trial tests whether a traditional Chinese exercise called Baduanjin can improve quality of life and emotional well-being in people with pancreatic cancer who are receiving chemotherapy. Researchers will enroll 96 patients and randomly assign them to either a 12-week Baduanji…

This study tests whether scheduled meditation using the Headspace app can improve recovery after pancreatectomy (surgery to remove part of the pancreas). Seventy patients will be asked to meditate regularly before and after surgery, and researchers will track pain, anxiety, sleep…

This study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …

This trial tests whether a short course of precisely targeted radiotherapy can safely reduce severe pain in people with advanced pancreatic cancer. The radiation is aimed at the coeliac plexus, a network of nerves in the abdomen that often causes pain when affected by the tumor. …

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests whether a 12-week supervised strength training program can help people with advanced pancreatic cancer maintain muscle mass and improve their quality of life. Ten participants who are receiving chemotherapy or immunotherapy will be randomly assigned to either the…

This study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…

This study tests a device called histotripsy, which uses focused ultrasound to break up tumors without cutting the skin. It is for people with abdominal tumors that cannot be surgically removed and are causing symptoms like pain. The goal is to see if the treatment improves quali…

This study will watch how doctors use a special camera (endoscopic ultrasound) to diagnose suspected pancreatic or bile duct diseases in 2500 adults across Lombardy, Italy. The goal is to see how accurate the procedure is, how safe it is, and how quickly patients get a final diag…

This study enrolls 150 adults with suspected or confirmed pancreatic cancer who are scheduled for chemotherapy. Researchers will collect tumor samples via endoscopic ultrasound before and during treatment to analyze gene activity. They aim to understand how the cancer changes acr…

This study looks at whether showing patients a short educational video before they sign consent for Whipple surgery (a complex operation for pancreas cancer) helps them understand the procedure better and feel more satisfied. About 60 adults will be split into two groups: one get…

This observational study is investigating whether certain blood markers and gut microorganisms can help identify people with chronic pancreatitis who are at higher risk of developing pancreatic cancer. Researchers will compare healthy individuals, those with chronic pancreatitis,…

This study collects and organizes data from 3,000 real pancreatic cancer patients, including those with early, advanced, and inoperable disease. Medical experts will label and structure the information to create a high-quality knowledge base. The goal is to train artificial intel…

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…

This study will examine whether certain workplace chemicals or tasks increase the risk of biliary tract and pancreatic cancers. Researchers will compare detailed work histories of 210 cancer patients from two earlier trials with healthy volunteers. The goal is to identify occupat…

This study tests whether a digitally supported prehabilitation program is feasible for patients awaiting major surgery for cancers of the pancreas, liver, stomach, or esophagus. The program includes supervised exercise, nutritional counseling, psychological support, and digital t…

This study looks at why some patients develop blood clots after pancreatic surgery that also involves removing a piece of a major vein. Researchers will collect information from over 1,000 patients across many hospitals to see how surgical techniques and blood-thinning medication…

This study will follow 800 people, including those with chronic pancreatitis, pancreatic cancer, and healthy volunteers, to learn why some pancreatitis patients later get pancreatic cancer. Participants give blood samples and health info; some may also provide tissue samples. Res…

This study is a registry that collects medical information and biological samples from up to 100,000 people with gastrointestinal cancers, such as pancreatic or colorectal cancer. No new treatments or drugs are given. The goal is to gather real-world data to help researchers answ…

This study tests whether a new real-time imaging method can make radiation therapy more accurate for cancer patients. About 40 adults with various cancers will receive their normal radiation treatment while the new imaging tracks the tumor in real time. The goal is to see if the …

This study aims to see if using a patient's genetic signature to choose chemotherapy can improve outcomes for people with borderline resectable pancreatic cancer. About 367 participants will receive standard chemotherapy, and researchers will track how long they live without majo…

This study interviews 20 pancreatic cancer patients to learn why certain groups—like racial minorities, low-income individuals, or rural residents—are less likely to join clinical trials. Researchers hope to find ways to make trials more accessible and fair for everyone. The stud…

This study looks at whether tumor DNA found in blood or peritoneal fluid can predict the spread of digestive cancers (stomach, colon, pancreas) to the lining of the abdomen. Researchers will follow 300 patients with early-stage tumors to see if those with positive DNA markers are…

This study looks at whether a blood test can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, ovarian, or pancreatic cancer. Researchers will collect blood and tumor samples from 300 adults to analyze cancer cells and their DN…

This study will test whether intermittent fasting (eating only during an 8-hour window each day) is safe and doable for 20 people at high risk for pancreatic cancer. Researchers will also check if this eating pattern changes certain markers in the body linked to cancer risk. The …

This study looks at a new way to detect cancer cells in the portal vein blood of people with pancreatic cancer. The goal is to see if these cells can warn early if the cancer comes back or spreads. The study will involve 20 participants and uses a special ultrasound-guided proced…

This observational study will enroll 185 people with metastatic pancreatic cancer to see if analyzing tumor genes and lab-grown organoids can predict which standard chemotherapy regimens work best. Researchers will compare predicted drug sensitivity to actual patient outcomes. Th…

This study compares two ways to reconnect the digestive tract after pancreatic cancer surgery (Whipple procedure). The goal is to see which method reduces delayed stomach emptying, a common complication. About 124 adults having this surgery will be randomly assigned to one of the…

This study will create a biobank by collecting blood, tissue, and bile samples from 300 adults with liver, bile duct, or pancreatic tumors, as well as from people with benign conditions and healthy volunteers. No experimental treatments or extra procedures are involved—samples ar…

This study will follow 200 adults undergoing surgery for liver, esophagus, or pancreatic cancer. Researchers want to see how patients' expectations before surgery relate to their pain, painkiller use, and recovery afterward. The goal is to learn how to better manage pain and impr…